Thermo Fisher Scientific Inc. has completed the acquisition of Phadia of Uppsala, Sweden, a provider of blood tests for the clinical diagnosis and monitoring of allergies and autoimmune diseases. Phadia now is part of Thermo Fisher’s Specialty Diagnostics business. The company is expected to contribute $0.07 to Thermo Fisher’s 2011 full-year adjusted earnings per share (EPS), an increase of $0.01 over the original estimate. Because of the favorable financing rates for the fourth quarter, the US company has adjusted its full-year EPS, which could result in a 20% to 23% EPS growth over 2010, it said. In addition, Phadia is expected to add $190 million to the company’s 2011 revenue results, about a 12% growth in revenue over 2010. For more information, visit: www.thermofisher.com